Journal of IiME Volume 3 Issue 1 www.investinme.org P PRROOFFIILLEESS ooff PPRREESSEENNTTEERRSS aatt tthhee IINNVVEESSTT iinn MMEE I INNTTEERRNNAATTIIOONNAALL MMEE//CCFFSS CCOONNFFEERREENNCCEE to come to our clinic. So I introduced the concept of an ambulatory team that could go home to people helping to get the correct diagnosis and offering them the same advice with up to five visits by two from the team each time. The limitation is that we must be able to do the visit in one day including transportation, so we cover only eastern Norway. These services have just started and now the South-Eastern Norway Regional Health Authority have asked Oslo University Hospital, Ullevaal (three University hospitals in Oslo joined by January 1st 2009) to investigate the possibility of starting an in-patient service for severe ME-sufferers, which would cover the whole country. The ward would provide the possibility for careful examination to rule out all other conditions that might explain the condition and give those who can profit from treatment/coaching that possibility. Our biggest concern at this time is that patients with very severe ME will be too ill to be moved to the ward and might become worse by physical examinations. The report is handed over to the authority by April 30th and we hope to have an answer by mid June. P Prrooffeessssoorr KKeennnnyy DDee MMeeii rr lleeii rr MMDD PPhhDD Dr. De Meirleir is a world renowned researcher and is professor of Physiology and Internal Medicine at Free University of Brussels in Belgium. He is co-editor of Chronic Fatigue Syndrome: A Biological Approach, and reviewer for more than 10 other medical journals. Dr. De Meirleir was one of four international experts on the panel that developed the Canadian Consensus Document for ME/CFS. He assesses/treats 3,000 to 4,000 ME/CFS patients annually. Professor Kenny L. De Meirleir, MD received his medical degree at Vrije Universiteit Brussel, Magna cum laude. His research activities in Chronic Fatigue date back to 1990. His other research activities in exercise physiology, metabolism and endocrinology have led to the Solvay Prize and the NATO research award. He is director of the Himmunitas Foundation Brussels and Professor at the Vrije Universiteit Brussel, as well as consultant in the Division of Cardiology and director of the cardiac rehabilitation program at Vrijie Universiteit Brussel. P Prreesseennttaatt iioonn PPrrooffeessssssoorr DDee MMeeii rr lleeii rr :: R Reesseeaarrcchh oonn EEeexxtt rreemmeellyy DDeebbii ll ii ttaatteedd MM..EE .. PPaatt iieenntt ss RReevveeaall ss tthhee TT rruuee N Naattuurree ooff tthhee DDii ssoorrddeerr Kenny De Meirleir(1), Chris Roelant(2), Marc Fremont(2), Kristine Metzger(2), Henry Butt(3) (1) Vrije Universiteit Brussel & HIMMUNITAS foundation, Brussels, Belgium (2) Protea Biopharma, Brussels, Belgium (3) Bioscreen & Bio 21, University of Melbourne, Melbourne, Australia In this study we compared totally bedridden patients (Karnofski score 20-30) with less ill ME patients (Karnofski score 60-70), family controls, contact controls and non-contact controls. EBV, HHV6 and Borna virus titers were not different in the three groups. Plasma LPS distinguished the groups, with the highest values in the bedridden patients. LPS is a strong activator of the immune system and high plasma concentrations suggest a hyperpermeable gut. There are many possible causes for this, but a lack of ‘local’ energy production is one of them. In a separate study (In Vivo, in press) we observed intestinal overgrowth of Gram positive D/L lactate producing Invest in ME (Charity Nr. 1114035) Page 68/76
69 Publizr Home